Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial
Introduction. Studies have shown that T2DM is an inflammatory disease. Thus, the present study was aimed at evaluating whether diacerein could improve the metabolic and inflammatory profile among patients with T2DM under long-term treatment with glucose-lowering agents. Methods. This is a double-bli...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/4246521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849472856210014208 |
|---|---|
| author | Glaucia S. Tres Sandra C. Fuchs Fabiana Piovesan Patricia Koehler-Santos Fernanda dos S. Pereira Suzi Camey Hugo K. Lisboa Leila B. Moreira |
| author_facet | Glaucia S. Tres Sandra C. Fuchs Fabiana Piovesan Patricia Koehler-Santos Fernanda dos S. Pereira Suzi Camey Hugo K. Lisboa Leila B. Moreira |
| author_sort | Glaucia S. Tres |
| collection | DOAJ |
| description | Introduction. Studies have shown that T2DM is an inflammatory disease. Thus, the present study was aimed at evaluating whether diacerein could improve the metabolic and inflammatory profile among patients with T2DM under long-term treatment with glucose-lowering agents. Methods. This is a double-blind, parallel, placebo-controlled trial with 72 participants randomly assigned to diacerein 50 mg or placebo for 12 weeks. The primary endpoint was the between-group difference in change in HbA1c. Secondary endpoints included the proportion of patients achieving metabolic control [HbA1c≤7.0% (53 mmol/mol)] and change in inflammatory mediators. Results. Participants in the diacerein group had greater reductions in mean HbA1c level in comparison to placebo (−0.98; 95% CI: −2.02 to 0.05, P=0.06), independently of confounding factors. The difference in HbA1c level was −1.3 (95% CI: −2.3 to −0.4) in favor of diacerein (P=0.007) in those with <14 years of diabetes duration versus 0.05 (−0.7 to 0.8; P=0.9) in those with longer duration. The diacerein group had a 50% increase in the number of participants at the lowest TNF-α level (≤1.46 pg/mL). Conclusions. In patients with long-established T2DM under long-term treatment with glucose-lowering agents, diacerein improves metabolic control as measured by HbA1c level and has a favorable impact on inflammatory profile. Clinical Trial Registry. This trial is registered with Brazilian Clinical Trials Registry (ReBEC) number RBR-29j956. |
| format | Article |
| id | doaj-art-d8f0f36256a84365a22b9a5532bfcb71 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-d8f0f36256a84365a22b9a5532bfcb712025-08-20T03:24:22ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/42465214246521Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled TrialGlaucia S. Tres0Sandra C. Fuchs1Fabiana Piovesan2Patricia Koehler-Santos3Fernanda dos S. Pereira4Suzi Camey5Hugo K. Lisboa6Leila B. Moreira7Postgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, BrazilPostgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, BrazilPostgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, BrazilUnidade de Análises Moleculares e de Proteínas (UAMP), Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2350, 90035-903 Porto Alegre, RS, BrazilUnidade de Análises Moleculares e de Proteínas (UAMP), Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2350, 90035-903 Porto Alegre, RS, BrazilPostgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, BrazilHospital São Vicente de Paulo, School of Medicine, Universidade de Passo Fundo (UPF), R. Teixeira Soares 808, 99010-080 Passo Fundo, RS, BrazilPostgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, BrazilIntroduction. Studies have shown that T2DM is an inflammatory disease. Thus, the present study was aimed at evaluating whether diacerein could improve the metabolic and inflammatory profile among patients with T2DM under long-term treatment with glucose-lowering agents. Methods. This is a double-blind, parallel, placebo-controlled trial with 72 participants randomly assigned to diacerein 50 mg or placebo for 12 weeks. The primary endpoint was the between-group difference in change in HbA1c. Secondary endpoints included the proportion of patients achieving metabolic control [HbA1c≤7.0% (53 mmol/mol)] and change in inflammatory mediators. Results. Participants in the diacerein group had greater reductions in mean HbA1c level in comparison to placebo (−0.98; 95% CI: −2.02 to 0.05, P=0.06), independently of confounding factors. The difference in HbA1c level was −1.3 (95% CI: −2.3 to −0.4) in favor of diacerein (P=0.007) in those with <14 years of diabetes duration versus 0.05 (−0.7 to 0.8; P=0.9) in those with longer duration. The diacerein group had a 50% increase in the number of participants at the lowest TNF-α level (≤1.46 pg/mL). Conclusions. In patients with long-established T2DM under long-term treatment with glucose-lowering agents, diacerein improves metabolic control as measured by HbA1c level and has a favorable impact on inflammatory profile. Clinical Trial Registry. This trial is registered with Brazilian Clinical Trials Registry (ReBEC) number RBR-29j956.http://dx.doi.org/10.1155/2018/4246521 |
| spellingShingle | Glaucia S. Tres Sandra C. Fuchs Fabiana Piovesan Patricia Koehler-Santos Fernanda dos S. Pereira Suzi Camey Hugo K. Lisboa Leila B. Moreira Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial Journal of Diabetes Research |
| title | Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial |
| title_full | Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial |
| title_fullStr | Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial |
| title_full_unstemmed | Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial |
| title_short | Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial |
| title_sort | effect of diacerein on metabolic control and inflammatory markers in patients with type 2 diabetes using antidiabetic agents a randomized controlled trial |
| url | http://dx.doi.org/10.1155/2018/4246521 |
| work_keys_str_mv | AT glauciastres effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT sandracfuchs effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT fabianapiovesan effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT patriciakoehlersantos effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT fernandadosspereira effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT suzicamey effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT hugoklisboa effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial AT leilabmoreira effectofdiacereinonmetaboliccontrolandinflammatorymarkersinpatientswithtype2diabetesusingantidiabeticagentsarandomizedcontrolledtrial |